Negatively charged gold nanoclusters protect against diabetic cardiomyopathy by inhibiting mitophagy
暂无分享,去创建一个
Dan Li | Zuqiang Shi | Chang Liu | P. Zhuang | Xiaolei Shen | X. Mei | Yangyang Yu
[1] K. Varga,et al. Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions , 2020, Nature Communications.
[2] T. Dawson,et al. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease , 2020, Molecular Neurodegeneration.
[3] S. Houser,et al. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control , 2018, Front. Physiol..
[4] Tsung-Rong Kuo,et al. Biomedical Applications for Gold Nanoclusters: Recent Developments and Future Perspectives , 2018, Nanoscale Research Letters.
[5] S. Sollott,et al. Mitochondrial membrane potential. , 2017, Analytical biochemistry.
[6] R. Jin,et al. Evolution from the plasmon to exciton state in ligand-protected atomically precise gold nanoparticles , 2016, Nature Communications.
[7] Hao Xu,et al. PINK1-Parkin-Mediated Mitophagy Protects Mitochondrial Integrity and Prevents Metabolic Stress-Induced Endothelial Injury , 2015, PloS one.
[8] G. Lopaschuk,et al. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy , 2014, British journal of pharmacology.
[9] J. Enkovaara,et al. Birth of the localized surface plasmon resonance in monolayer-protected gold nanoclusters. , 2013, ACS nano.
[10] P. Schulze,et al. Lipid metabolism and toxicity in the heart. , 2012, Cell metabolism.
[11] U. Kompella,et al. Functionalized nanosystems for targeted mitochondrial delivery. , 2012, Mitochondrion.
[12] Atsushi Tanaka,et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.
[13] W. Lederer,et al. Probing the outer mitochondrial membrane in cardiac mitochondria with nanoparticles. , 2007, Biophysical journal.
[14] Thomas H Marwick,et al. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.
[15] J. Sowers,et al. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease , 2017, Diabetologia.